Pemvidutide Peptide: MASH, Liver Fat and Weight-Loss Evidence
Evidence-aware pemvidutide guide covering GLP-1/glucagon mechanism, MASH phase 2b results, liver-fat data, weight loss and safety limits.
Pemvidutide is one of the clearer examples of a pipeline peptide where the marketing shorthand can get ahead of the data. It is a once-weekly investigational peptide with balanced GLP-1 and glucagon receptor agonist activity. Altimmune is developing it primarily for metabolic dysfunction- associated steatohepatitis, or MASH, with additional studies in alcohol use disorder and alcohol-associated liver disease.
The search interest is easy to understand. Pemvidutide sits near survodutide, retatrutide, cagrilintide, and other next-generation metabolic peptides. It has human liver-fat data, a biopsy-based phase 2b MASH study and weight-loss signals. It also has a built-in caution: the key 24-week IMPACT trial met the MASH resolution endpoint but did not meet the fibrosis improvement endpoint at that timepoint.
That distinction matters. Pemvidutide is not an approved MASH drug, not an approved weight-loss drug, and not a substitute for regulated GLP-1 medicines. It is a serious investigational peptide with human evidence that still needs longer and larger confirmation.
This guide is educational and not medical advice. MASH, obesity, diabetes, alcohol use disorder and liver fibrosis require clinician-directed evaluation. Trial protocols and investigational dose levels are not personal dosing instructions.
Pemvidutide At A Glance
| Question | Evidence-aware answer |
|---|---|
| Other names | ALT-801, MD-1373, SP-1373 |
| Drug type | Investigational GLP-1/glucagon dual agonist peptide |
| Developer | Altimmune |
| Main development focus | MASH, alcohol use disorder and alcohol-associated liver disease |
| Route in trials | Once-weekly subcutaneous injection |
| FDA status | Investigational as of July 8, 2026 |
| Best current evidence | Human MASLD and MASH trials with liver-fat, MASH resolution and weight outcomes |
| Main limitation | Fibrosis improvement is not established, and no FDA label exists |
For wider context, compare the weight-loss peptide hub, peptides for weight loss, and the GLP-1 receptor agonist guide. For pipeline context, see Amgen, Sanofi and other GLP-1 programs.
How GLP-1 And Glucagon Agonism Fit Together
Pemvidutide combines two receptor pathways. GLP-1 receptor activation is the familiar incretin signal used by approved medicines such as semaglutide and tirzepatide-containing products. It supports appetite reduction, glucose- dependent insulin secretion and slower gastric emptying.
Glucagon receptor activation is the liver-focused part of the strategy. Glucagon biology is tied to hepatic fuel handling, fatty acid oxidation and lipid metabolism. The development hypothesis is that a GLP-1/glucagon dual agonist could combine weight loss with more direct liver-fat and inflammation effects than a single-pathway GLP-1.
That mechanism is plausible, but mechanism is not proof. The reason pemvidutide deserves a standalone guide is the human trial evidence, not the theory alone. The useful question is whether the clinical endpoints line up: MASH resolution, fibrosis improvement, liver-fat reduction, weight change, lipids, tolerability and longer-term safety.
What The 24-Week IMPACT MASH Trial Found
The IMPACT trial is the central evidence source. It is an international, randomized, double-blind, placebo-controlled phase 2b trial in people with biopsy-confirmed MASH and fibrosis stage F2 or F3. Participants were assigned to once-weekly pemvidutide 1.2 mg, pemvidutide 1.8 mg or placebo. The study was designed with dual primary endpoints at 24 weeks: MASH resolution without worsening of fibrosis, and at least one-stage fibrosis improvement without worsening of MASH.
The 24-week result was mixed in a specific way:
| Endpoint at 24 weeks | Placebo | Pemvidutide 1.2 mg | Pemvidutide 1.8 mg | Interpretation |
|---|---|---|---|---|
| MASH resolution without worsening of fibrosis | 20% | 58% | 52% | Pemvidutide met this endpoint versus placebo. |
| Fibrosis improvement without worsening of MASH | 28% | 33% | 36% | Differences were not statistically significant at 24 weeks. |
| Discontinuation due to adverse events | 2% | 0% | 1% | Low discontinuation rates in the abstract. |
The most evidence-aware reading is simple: pemvidutide showed a strong MASH resolution signal at 24 weeks, while fibrosis improvement remained unproven at that timepoint. That is not a failed program, but it is also not a complete MASH approval story.
Altimmune later described 48-week IMPACT data and ongoing development, but the most conservative article language should still separate company update, conference material and peer-reviewed PubMed-indexed trial data.
Liver Fat Data From MASLD Studies
A separate randomized controlled MASLD study extension followed participants for 24 weeks and measured liver fat content by MRI-proton density fat fraction. The study reported substantial relative reductions in liver fat content with pemvidutide compared with placebo.
| Group | Relative liver-fat reduction at 24 weeks |
|---|---|
| Placebo | 14.0% |
| Pemvidutide 1.2 mg | 56.3% |
| Pemvidutide 1.8 mg | 75.2% |
| Pemvidutide 2.4 mg | 76.4% |
At the 1.8 mg dose, 84.6% of participants achieved at least 50% liver-fat reduction and 53.8% achieved normalization to 5% or less liver fat content. Body weight was also reduced by 6.2% over 24 weeks in the study abstract.
This evidence supports a liver-fat effect in a studied MASLD population. It does not prove that liver fibrosis improves, that cirrhosis outcomes improve, or that unregulated pemvidutide products reproduce trial exposure. Liver fat, MASH histology and fibrosis are related but not identical endpoints.
Weight-Loss Context
Pemvidutide is often discussed beside obesity drugs because GLP-1 agonism reduces appetite and because liver-disease trials have shown body-weight changes. That does not make pemvidutide an approved obesity drug.
The practical comparison looks like this:
| Compound | Main receptor profile | Status | Why it is compared with pemvidutide |
|---|---|---|---|
| Semaglutide | GLP-1 | Approved under specific brands | Approved GLP-1 benchmark for weight and metabolic outcomes. |
| Tirzepatide | GIP and GLP-1 | Approved under specific brands | Approved dual-incretin benchmark. |
| Survodutide | GLP-1 and glucagon | Investigational | Same broad dual-agonist class, separate molecule and trials. |
| Retatrutide | GIP, GLP-1 and glucagon | Investigational | Triple-agonist comparator with obesity-focused development. |
| Pemvidutide | GLP-1 and glucagon | Investigational | Liver-disease-forward dual agonist with weight-loss signals. |
For people searching "pemvidutide weight loss," the answer should stay narrow: human evidence indicates weight reduction in studied liver-disease and metabolic populations, but pemvidutide is not an FDA-approved weight-management medicine. Use GLP-1 drugs list and FDA-approved GLP-1 drugs for weight loss for approved options.
Safety And Tolerability Signals
The IMPACT 24-week abstract reported adverse events in 78% of participants in the 1.2 mg group, 81% in the 1.8 mg group and 67% in the placebo group. Most events were described as mild or moderate. Discontinuation due to adverse events was low in the abstract: none in the 1.2 mg group, one participant in the 1.8 mg group and two participants in placebo.
A GRADE-assessed meta-analysis of randomized trials reported hepatic and metabolic improvements and described nausea as mostly mild to moderate. That is useful, but meta-analysis can only be as strong as the underlying trials and follow-up. Larger phase 3 trials are still needed to define uncommon adverse events, long-term tolerability, diabetes subgroup effects, gallbladder or pancreatic risks, body-composition effects and outcomes beyond surrogate markers.
Readers should also separate clinical-trial pemvidutide from market products. An investigational drug supplied in a controlled trial is not the same as a research vial or online compounded claim. For general safety filters, read the peptide COA guide, peptide storage guide and peptide cancer risk guide.
How To Evaluate Pemvidutide Claims
Use this checklist before trusting a headline, forum protocol or vendor page:
| Claim | Better question |
|---|---|
| "Pemvidutide treats MASH" | Is the source naming MASH resolution, fibrosis improvement or only liver-fat reduction? |
| "Fibrosis improved" | Was it statistically significant, and at which timepoint? |
| "No titration needed" | Was that a trial design detail, or a personal dosing claim? |
| "Like survodutide" | Does the source distinguish separate molecules, trials and sponsors? |
| "Available now" | Available as a clinical-trial drug, future prescription product or unregulated research material? |
| "Better than GLP-1" | Was there a direct head-to-head trial against an approved GLP-1? |
Reddit and peptide forums are useful for discovering what people are asking: MASH results, liver fat, glucagon agonism, nausea, body composition and whether pemvidutide is "like survodutide." They are not evidence for dosing, safety or clinical benefit.
What To Watch Next
The most important next evidence is longer-duration, larger phase 3 data. A MASH program needs to show more than early resolution signals. The higher bar is fibrosis improvement, durability, safety, cardiometabolic outcomes, diabetes subgroup performance and real regulatory labeling.
Practical watch points:
- Whether fibrosis improvement separates more clearly with longer treatment.
- Whether MASH resolution persists beyond 24 weeks.
- How weight loss, liver enzymes, liver stiffness and ELF scores move together.
- Whether tolerability holds in larger and more diverse populations.
- Whether alcohol-related liver disease and alcohol use disorder studies show signals that are distinct from weight-loss effects.
The peptide half-life guide and accumulation calculator can help explain repeated- dose exposure concepts, but they do not validate investigational dosing.
Bottom Line
Pemvidutide is a serious investigational peptide because it has human liver-fat data and a biopsy-based phase 2b MASH trial. The strongest current evidence is MASH resolution without worsening of fibrosis at 24 weeks, plus liver-fat and weight reductions in studied populations.
The limit is just as important: fibrosis improvement was not established at the 24-week IMPACT timepoint, pemvidutide is not FDA approved, and longer trials are needed before it can be judged as a regulated MASH or weight-management therapy. Treat it as a pipeline peptide with credible human evidence, not as a ready-made consumer protocol.
References
Altimmune. Pemvidutide. Company pipeline page. Accessed July 8, 2026.
Noureddin M, et al. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. Lancet. 2025.
Browne SK, et al. Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial. JHEP Rep. 2025.
Rajab I, et al. Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials. Naunyn Schmiedebergs Arch Pharmacol. 2026.
Newsome PN. The dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial. Lancet. 2025.
ClinicalTrials.gov. Study of Pemvidutide in Subjects With MASH. NCT05989711.
ClinicalTrials.gov. Study of Pemvidutide in Subjects With Non-alcoholic Fatty Liver Disease. NCT05292911.